Opioid rotation for cancer pain: Rationale and clinical aspects

Cancer

Volumn 86, Issue 9, 1999, Pages 1856-1866

  Mercadante, Sebastiano ^a,b  

^a LA MADDALENA CANCER CENTER   (Italy)

^b SAMOT Onlus   (Italy)

Author keywords

Cancer pain; Methadone; Morphine metabolites; Opioid rotation; Opioid toxicity; Opioids; Tolerance; Transdermal route

Indexed keywords

DIAMORPHINE; DIZOCILPINE; FENTANYL; HYDROMORPHONE; METHADONE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OPIATE AGONIST; SUFENTANIL;

ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; CANCER PAIN; COMA; DROWSINESS; DRUG CHOICE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERANCE; HUMAN; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; RESPIRATION DEPRESSION; SUBCUTANEOUS DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION; TREATMENT PLANNING; VOMITING;

ANALGESICS, OPIOID; FENTANYL; HUMANS; HYDROMORPHONE; METHADONE; MORPHINE; NARCOTICS; NEOPLASMS; PAIN;

EID: 0033229732     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G     Document Type: Article

References (109)

1. Hanks GW, Justins D. Cancer pain: management. Lancet 1992;339:1031-6.
2. Hanks GW, De Conno F, Ripamonti C, Hanna M, McQuay HJ, Mercadante S, et al. Morphine in cancer pain: modes of administration. BMJ 1996;312:828-6.
3. Crews JC, Sweeney NJ, Denson DD. Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist for management of terminal cancer pain. Cancer 1993;72:2266-72.
4. Morley JS, Watt JWG, Wells JC, Miles JB, Finnegan MJ, Leng G. Methadone in pain uncontrolled by morphine. Lancet 1993;342:1243.
5. Galer BS, Coyle N, Pasternak GW, Portenoy RK. Individual variability in the response to different opioids: report of five cases. Pain 1992;49:87-91.
6. Pasternak GW, Wood PL. Multiple mu receptors. Life Sci 1986;38:1889-98.
7. Bruera E, MacMillan D, Hanson J, MacDonald RN. The Edmonton staging system for cancer pain: preliminary report. Pain 1989;37:203-10.
8. Portenoy RK. Tolerance to opioid analgesic: clinical aspects. In: Hanks GW, editor. Palliative medicine: problem areas in pain and symptom management. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1994:49-66.
9. Desmeules JA, Kayser V, Guilbaud G. Selective opioid receptor agonists modulate mechanical allodynia in an animal model of neuropathic pain. Pain 1993;53:277-85.
10. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995;10:378-84.
11. Watanabe S, Bruera E. A practical approach to opioid responsiveness in cancer pain. Progr Palliat Care 1994;2: 182-5.
12. Russell RD, Chang KJ. Alternated delta and mu receptor activation: a stratagem for limiting opioid tolerance. Pain 1989;36:381-9.
13. Ivarsson M, Neil A. Differences in efficacies between morphine and methadone demonstrated in guinea pig ileum. Pharmacol Toxicol 1989;65:368-71.
14. Mogil JS, Stemberg WF, Marek P, Sadowski B, Belknap JK, Liebeskind JC. The genetics of pain and pain inhibition. Proc Natl Acad Sci USA 1996;93:3048-55.
15. Mogil JS, Kest B, Sadowski B. Belknap JK. Differential genetic mediation of sensitivity to morphine in genetic models of opiate antinociception: influence of nociceptive assay. J Pharmacol Exp Ther 1996;276:532-44.
16. Neil A. Morphine and methadone tolerant mice differ in cross-tolerance to other opiates. Naunyn-Schmiedeberg's Arch Pharmacol 1982;320:50-3.
17. Pick CG, Cheng J, Paul D, Pasternak GW. Genetic influences in opioid analgesic sensitivity in mice. Brain Res 1991;566: 295-8.
18. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 1990;43:273-86.
19. Sosnowski M, Yaksh TL. Differential cross-tolerance between intrathecal morphine and sufentanil in the rat. Anesthesiology 1990;73:1141-7.
20. Mao J, Price D, Mayer DJ. Experimental neuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanism involved in morphine tolerance and neuropathic pain. Pain 1995;61:353-64.
21. Mercadante S. Ketamine in cancer pain. Palliat Med 1996; 10:225-30.
22. Andersen S, Dickenson AH, Kohn M, Reeve A, Rahman W, Ebert B. The opioid ketobemidone has a NMDA blocking effect. Pain 1996;67:369-74.
23. Ebert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett 1995;187:165-8.
24. Duttaroy A, Yoburn BC. The effect of intrinsic efficacy on opioid tolerance. Anesthesiology 1995;82:1226-36.
25. Dirig DM, Yaksh TL. Differential right shifts in the dose-response curve for intrathecal morphine and sufentanil as a function of stimulus intensity. Pain 1995;62:321-8.
26. Kissin I, Brown P, Bradley E. Magnitude of acute tolerance to opioids is not related to their potency. Anesthesiology 1991; 75:813-6.
27. Frenk H, Watkins LR, Mayer DJ. Differential behavioral effects induced by intrathecal microinjection of opiates: comparison of convulsive and cataleptic effects produced by morphine, methadone, and D-ala-methionine-enkephalinamide. Brain Res 1984;299:31-42.
28. Saeki S, Yaksh TL. Suppression of nociceptive responses by spinal mu opioid agonists: effects of stimulus intensity and agonist efficacy. Anesthesiol Analg 1993;77:265-74.
29. Mercadante S. Methadone in cancer pain. Eur J Pain 1997; 1:77-85.
30. Faura CC, Olaso MJ, Cabanes CG, Horga JF. Lack of morphine-6-glucuronide antinociception after morphine treatment. Is morphine-3-glucuronide involved? Pain 1996;65; 25-30.
31. France B, Gout R, Monsarrat B, Cros J, Zajac JM. Further evidence that morphine-6-glucuronide is a more potent opioid agonist that morphine. J Pharmacol Exp Ther 1992; 262:25-31.
32. Gong QL, Hedner J, Bjorkman R, Hedner T. Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression. Pain 1992;48:249-55.
33. Smith MT, Watt JA, Crammond T. Morphine-3-glucuronide - a potent antagonist of morphine analgesia. Life Sci 1990; 47:579-85.
34. Osborne R, Joel S, Trew D, Slevin M. Morphine and morphine metabolite behaviour after different routes of administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Clin Biochem 1990;47:12-9.
35. Peterson GM, Randall CTC, Paterson J. Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. Ear J Clin Pharmacol 1990;38:121-4.
36. Sawe J. High-dose morphine and methadone in cancer patients: clinical considerations of oral treatment. Clin Pharmacokinet 1986;11:87-106.
37. D'Honneur G, Gilton A, Sandouk P, Schermann JM, Duvaldestin P. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine. The influence of renal failure. Anesthesiology 1994;81: 87-93.
38. Osborne RJ, Joel SP, Slevin ML. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. BMJ 1986; 292:1548-9.
39. Portenoy RK, Foley KM, Stulman J, Khan E, Adelhardt J, Layman M, et al. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain 1991;47:13-9.
40. Calleja MA, Childs D, Venn RF, Michalkiewicz A. Persistently increased morphine-6-glucuronide concentrations. Br J Anaesthesiol 1990;64:649.
41. Bowsher D. Paradoxical pain. BMJ 1993;306:473.
42. Goucke CR, Hackett LP, Ilett KF. Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine-resistant pain. Pain 1994;56:145-9.
43. Woolf T, Samuelsson H, Hedner T. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration. Pain 1995;62:147-54.
44. Sjogren P, Jonsson T, Jensen NH, Drenck NE, Jensen TS. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain 1993; 55:93-7.
45. Zaw-Tun N, Bruera E. Active metabolites of morphine. J Palliat Care 1992;8:48-50.
46. Hagen NA, Foley KM, Cerbone DJ, Portenoy RK, Inturrisi CE. Chronic nausea and morphine-6-glucuronide. J Pain Symptom Manage 1991;6:125-8.
47. Sjogren P, Dragsted L, Christensen CB. Myoclonic spasm during treatment with high doses of intravenous morphine in renal failure. Acta Anaesthesiol Scand 1993;37:780-2.
48. Sjogren P, Jensen NH, Jensen TS. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting with other opioid agonists. Pain 1994;59:313-6.
49. Tiseo PJ, Thaler HT, Lapin J, Inturrisi CE, Portenoy RK, Foley KM. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain 1995; 61:47-54.
50. Glare PA, Walsh TD, Pippenger CE. Normorphine, a neurotoxic metabolite? Lancet 1990;335:725-8.
51. Kaiko RK, Foley K, Grabinski PY, Heidrich G, Rogers AG, Inturrisi CE, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 1983;13:150-85.
52. Babul N, Darke AC. Putative role of hydromorphone metabolites in myoclonus. Pain 1992;51:260-1.
53. Eisele JH, Grisby EJ, Dea G. Clonazepam treatment of myoclonic contractions associated with high-dose opioids: case report. Pain 1992;49;213-5.
54. Fainsinger R, Schoeller T, Boiskin M, Bruera E. Cognitive failure and coma after renal failure in a patient receiving captopril and hydromorphone. J Palliat Care 1993;9:53-5.
55. Mercadante S. Predictive factors and opioid responsiveness in cancer pain. Eur J Cancer 1998;34:627-31.
56. Gannon C. The use of methadone in the care of the dying. Eur J Palliat Care 1997;4:152-8.
57. Hanks GW, Forbes K. Opioid responsiveness. Acta Anaesthesiol Scand 1997;41:154-8.
58. Fallon M. Opioid rotation: does it have a role? Palliat Med 1997;11:177-8.
59. Cherny NJ, Chang V, Frager G, Ingham JM, Tiseo PJ, Popp B, et al. Opioid pharmacotherapy in the management of cancer pain. Cancer 1995;76;1288-93.
60. Schug SA, Zech D, Grond S, Jung H, Meuser T, Stobbe B. A long term survey of morphine in cancer pain patients. J Pain Symptom Manage 1992;7:259-66.
61. Fitzgibbon DR, Ready LB. Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion in the treatment of cancer pain refractory to high-dose morphine. Pain 1997;73:259-61.
62. Bruera E, Brenneis C, Michaud M, Bacovsky R, Chadwick S, Emeno A, et al. Use of the subcutaneous route for the administration of narcotics in patients with cancer pain. Cancer 1988;62:407-11.
63. Drexel H, Dzien A, Spiegel RW, Lang AH, Breier C, Abbrederis K, et al. Treatment of severe cancer pain by low-dose continuous subcutaneous morphine. Pain 1989;36:169-76.
64. Kalso E, Heiskanen T, Rantio M, Rosenberg PH, Vainio A. Epidural and subcutaneous morphine in the management of cancer pain: a double blind cross-over study. Pain 1996; 67:443-9.
65. Hogan Q, Haddox JD, Abram S, Weissman D, Taylor M, Janjan N. Epidural opiates and local anesthetics for the management of cancer pain. Pain 1991;46:271-9.
66. Bruera E, Macmillian K, Selmser P, MacDonald N, Decreased local toxicity with subcutaneous diamorphine (heroin): a preliminary report. Pain 1990;43:91-4.
67. Bruera E, Fainsinger R, Moore M, Thibault E, Spoldi V, Ventafridda V. Clinical note: local toxicity with subcutaneous methadone - experience of two centers. Pain 1991;45: 141-3.
68. Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996;78:852-7.
69. Ripamonti C, Zecca E, Brunelli C, Rizzio E, Saita L, Lodi F, et al. Rectal methadone in cancer patients with pain. A preliminary clinical and pharmacokinetic study. Ann Oncol 1995;6:841-3.
70. Warren DE. Practical use of rectal medications in palliative care. J Pain Symptom Manage 1996;11:378-87.
71. Weinberg DS, Inturrisi CE, Reidenberg E. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988;44:335-42.
72. Ahmezdai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manage 1997; 13:254-61.
73. Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996;64:527-34.
74. Janssen Pharmaceutica, Inc. Duragesic, fentanyl transdermal system (product monograph). Mississauga, Ontario: Janssen Pharmaceutica, Inc., 1991.
75. MacDonald N. Letter. J Pain Symptom Manage 1993;8: 320-1.
76. Fine PG, Marcus M, De Boer AJ, Van der Oord B. An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain 1991;45: 149-53.
77. Zech DFJ, Grond S, Lynch J, Dauer HG, Stollenwerk B, Lehmann KA. Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients. Pain 1992;50: 293-301.
78. Patt R. Letter. J Pain Symptom Manage 1993;8:322-3.
79. Korte W, Morant R. Transdermal fentanyl in uncontrolled cancer pain: titration on day-to-day basis as a procedure for safe and effective dose finding. A pilot study in 20 patients. Support Care Cancer 1994;2:123-7.
80. Davies AN, Bond C. Transdermal fentanyl and the opioid withdrawal syndrome. Palliat Med 1996;10:348.
81. Hunt R. Transdermal fentanyl and the opioid withdrawal syndrome. Palliat Med 1996;10:347-8.
82. Higgs CMB, Vella Brincat J. Withdrawal with transdermal fentanyl. J Pain Symptom Manage 1995;10:4-5.
83. Fainsinger R, Bruera E. The management of dehydration in terminally ill patients. J Palliat Care 1994;10:55-9.
84. Kirkham SR, Pugh R. Opioid analgesia in uraemic patients. Lancet 1995;345:1185.
85. Paix A, Coleman A, Lees J, Grigson J, Brooksbank M, Thorne D, et al. Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Pain 1995;61:263-9.
86. Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. Pain 1997;70:109-15.
87. Singer M, Noonan KR. Continuous intravenous infusion of fentanyl: case reports of use in patients with advanced cancer and intractable pain. J Pain Symptom Manage 1993;8: 215-20.
88. Kreek MJ, Schecter AJ, Gutjahr CL, Hecht M. Methadone use in patients with chronic renal disease. Drug Alcohol Depend 1980;5:197-205.
89. Bruera E, Schoeller T, Fainsinger RL, Kastelan C. Custom-made suppositories of methadone for severe cancer pain. J Pain Symptom Manage 1992;7:372-4.
90. Bruera E, Watanabe S, Fainsinger RL, Spachynski K, Suarez-Almazor M, Inturrisi C. Custom-made capsules and suppositories of methadone for patients on high dose opioids for cancer pain. Pain 1995;62:141-6.
91. Portnow JM, Corbett RJ. Oral methadone for relief of chronic pain from cancer. N Engl J Med 1982;306:889-990.
92. Leng G, Finnegan MJ. Successful use of methadone in nociceptive cancer pain unresponsive to morphine. Palliat Med 1994;8:153-5.
93. MacDonald N, Der L, Allen S, Champion F. Opioid hyperexcitability: the application of an alternate opioid therapy. Pain 1993;53:353-5.
94. Rimmer T, Trotman I. Methadone restores opioid sensitivity in cancer pain. Palliat Med 1996;10:58.
95. Manfredi PL, Borsook D, Chandler SW, Payne R. Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observation. Pain 1997;70:99-101.
96. Viganó A, Fan D, Bruera E. Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain 1996;67:115-9.
97. Hunt G, Bruera E. Respiratory depression in a patient receiving oral methadone for cancer pain. J Pain Symptom Manage 1995;10:401-4.
98. Lawlor P, Turner K, Hanson J, Bruera E. Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain 1997;72;79-85.
99. Bruera E, MacMillian K, Hansen J. The cognitive effect of the administration of narcotic analgesics in patients with cancer pain. Pain 1989;39:13-6.
100. Bruera E. Severe organic brain syndrome. J Palliat Care 1991;7:36-8.
101. Bruera E, Schoeller T, Montejo G. Organic hallucinosis in patients receiving high doses of opiates for cancer pain. Pain 1992;48:397-9.
102. Maddocks I, Somogyi A, Abbott F, Hayball P, Parker D. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage 1996;12:182-9.
103. Mercadante S, Caligara M, Sapio M, Serretta R, Lodi F. Subcutaneous fentanyl infusion in obstructed patient with renal failure. J Pain Symptom Manage 1997;13:241-4.
104. Lawlor PG, Turner KS, Hanson J, Bruera E. Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer 1998;82:1167-73.
105. Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 1998;16:3216-21.
106. Morley JS, Makin MK. Comments on Ripamonti et al. Pain 1997;73:14.
107. Mercadante S, Sapio M, Serretta R, Caligara M. Patient-controlled analgesia with oral methadone in cancer patients: preliminary report. Ann Oncol 1996;7:613-8.
108. Fitzgibbon DR, Ready LB. Intravenous high-dose methadone administered by patient controlled analgesia and continues infusion for the treatment of cancer pain refractory to high-dose morphine. Pain 1997;73:259-61.
109. Ripamonti C, De Conno F, Groff L, Belzile M, Pereira J, Hanson J, et al. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. Ann Oncol 1998;9:79-83.